Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064051 · ClinicalTrials.gov registry record · Phase 2
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Study locations
NCT00064051: Completed Phase 2 study of Pancreatic Cancer, sponsored by Vion Pharmaceuticals.
NCT00064051 is a Phase 2 study of Pancreatic Cancer that has completed, run by Vion Pharmaceuticals. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00064051, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving gemcitabine together with 3-AP works in treating patients with unresectable or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG gemcitabine hydrochloride
- DRUG triapine
Study Locations (7)
England
- Christie Hospital N.H.S. Trust - Manchester
- Royal Marsden NHS Foundation Trust - Surrey - Sutton
Illinois
- University of Chicago Cancer Research Center - Chicago
Indiana
- Indiana Oncology Hematology Consultants - Indianapolis
Minnesota
- University of Minnesota Cancer Center - Minneapolis
Tennessee
- Sarah Cannon Cancer Center at Centennial Medical Center - Nashville
Other
- Universitair Ziekenhuis Gent - Ghent
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00064051 record still lists
NCT00064051 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which gemcitabine hydrochloride is the first listed.
NCT00064051 lists 7 locations in 6 states (England, Illinois, Indiana).
Frequently Asked Questions
What is clinical trial NCT00064051 about?
NCT00064051 is a clinical study titled "3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help gemcitabine kill more cancer cells by making them m...
What is the current status of trial NCT00064051?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-01. Estimated completion is 2008-08.
What conditions does trial NCT00064051 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00064051?
The interventions under investigation include: gemcitabine hydrochloride (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00064051?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064051 being conducted?
This trial has 7 study locations across Illinois, Indiana, Minnesota, Tennessee, England. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia